This study aimed to examine the histopathological characteristics, treatment modalities, survival features, and factors influencing these traits in patients with neuroendocrine neoplasms (NEN) of the breast. We retrospectively reviewed the case records of breast NEN patients who were followed up in Ankara Numune Training and Research Hospital and Ankara City Hospital Medical Oncology clinics from December 2005 to June 2022. After noting their clinical and pathological features in survival files, the obtained data were analyzed and compared. Our single- center study included nine patients with breast NENs. Histologically, four (55.5%) and two (22.2%) patients exhibited well-differentiated neuroendocrine tumor (NET) and poorly differentiated neuroendocrine carcinoma (NEC), respectively. The last two (22.2%) patients showed an invasive breast carcinoma with neuroendocrine differentiation (IBC-NED). All patients underwent surgery after diagnosis. Of them, six (66.7%) and five (55.6%) patients received adjuvant chemotherapy and radiotherapy, respectively. The patients with diagnoses of IBC-NED and breast NEC as well as two patients diagnosed with well-differentiated breast NET received adjuvant chemotherapy. Moreover, all patients received hormonal therapy. The median overall and the median disease-free survival were 10.6 (7.3-13.8) years and 6.2 (1.1-11.3) years, respectively. It is essential to understand the biology of breast NENs to enhance the diagnosis, treatment, and patient outcomes. Hence, further research is warranted to elucidate the underlying mechanisms, validate potential therapeutic targets, and establish optimal management strategies for such patients.